Novo Holdings and TA Associates partner with Biocomposites to drive next chapter of its growth
- Editor
- Mar 3
- 1 min read
Whats Happening:
Novo Holdings is making an investment in Biocomposites, a medical devices company specializing in infection management products. TA Associates, Biocomposites' majority shareholder since 2017, will reinvest alongside Novo Holdings and the company's management. This partnership aims to accelerate Biocomposites' international expansion and product innovation.
Key Moves:
Novo Holdings invests in Biocomposites, joining TA Associates as a shareholder
TA Associates reinvests in Biocomposites alongside Novo Holdings
Partnership aims to accelerate Biocomposites' global expansion and product innovation
By The Numbers:
Biocomposites' products are used in over 1 million procedures annually
The company's products are trusted by surgeons in over 100 countries
Biocomposites has achieved a threefold increase in revenues since partnering with TA in 2017
Key Quotes:
"We are thrilled to partner with Biocomposites and TA in this exciting new chapter for the Company," said Henrik Kjær Hansen, Senior Partner at Novo Holdings.
"This investment is a significant validation of Biocomposites' achievements so far and our future prospects for growth," said Michael Harris, Biocomposites' CEO.
"The Company has consistently demonstrated its ability to scale internationally while building out a diversified product portfolio that aligns with growing market demand and meets evolving patient needs," said Birker Bahnsen, Managing Director at TA.
Bottom Line:
The investment from Novo Holdings and continued support from TA Associates positions Biocomposites for significant growth and innovation in the infection management space. This partnership is expected to enhance the company's global footprint and advance its product pipeline, potentially improving patient outcomes worldwide.
Comments